ABOUT US

COMPANY PROFILE

Amarin is a clinical-stage biopharmaceutical company with a lead program entering Phase 3 for hypertriglyceridemia.

Amarin’s cardiovascular programs capitalize on its expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in cardiovascular disease. Amarin's cardiovascular pipeline includes AMR101 entering Phase 3 for hypertriglyceridemia and a preclinical program of new lipid compounds.

Amarin’s pipeline also includes a range of candidates in development to treat central nervous system (CNS) disorders, all of which are available for partnering. The CNS pipeline comprises:
- AMR101 for Huntington’s disease
- EN101 for myasthenia gravis
- Sublingual apomorphine and AMR103 for Parkinson’s disease
- Nasal lorazepam for epilepsy

Amarin is headquartered in Dublin, Ireland, and is listed in the U.S. on NASDAQ (ticker: AMRN)

This page was last updated on October 9, 2008.